October 13, 2021 | Highland, MD – The Jayne Koskinas Ted Giovanis Foundation for Health and Policy has extended prior JKTGF funded research to Heiko Enderling, Ph.D., a faculty member of Moffitt Cancer Center, to support his work personalizing radiation therapy to better fight breast cancer.
It is now widely recognized that breast cancer therapy should be tailored to individual patients. While patient-specific data has affected the decision for use of chemotherapy, it has yet to impact radiation therapy, the single most used therapeutic treatment in oncology.
This research seeks to decipher the architecture of the tumor-immune ecosystem in biopsy tissues to identify the optimal radiation protocol – on a per-patient basis – to induce robust immunity and eradicate the tumor.
“Radiation therapy is the most used therapy for fighting breast cancer, yet no clinical trials have attempted to individualize it,” said Ted Giovanis, founder and president of the JKTG Foundation.
“Heiko’s research has challenged current practice with exciting results, and the Foundation is pleased to further support his work so future breast cancer patients benefit from individualized treatment and better outcomes.”
The intense impact of COVID-19 continues playing out in new headlines each day, but it’s important we step back – both as a medical community and as individuals – and consider the various ways we can prevent serious harm from this disease and others.
Registration is open for JKTG Foundation’s annual cancer research symposium held virtually October 28, 2021 from 1 – 3:30 p.m. EST. This year’s presentations and discussions will focus on immune cells and metastasis.
This Becker’s Healthcare podcast episode features Ted Giovanis, President at Jayne Koskinas Ted Giovanis Foundation for Health and Policy and Author of “Beyond Fear: How I Fought the Feds for Six Years—and Won”.